Showing results (81-90 of 143) with videos related to

Sort By:
Pageof 15
In Vivo (Athens, Greece)|October 30, 2025
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER StudyElisabetta Gambale, Roberta Giorgione, Umberto Basso, et al.
European Urology Open Science|October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Plos One|April 12, 2016
Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisPaolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Plos One|July 7, 2018
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in ItalyMaria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, et al.
Journal of Clinical Medicine|June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted TherapyVincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Urologic Oncology|June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancerRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Clinical Genitourinary Cancer|April 17, 2024
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Oncotarget|December 17, 2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysisDaniele Santini, Raffaele Ratta, Francesco Pantano, et al.
Future Oncology (London, England)|May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programSergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Pageof 15